@Article{Lis-Święty2010,
journal="Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii",
issn="1642-395X",
volume="27",
number="4",
year="2010",
title="Drug rash with eosinophilia and systemic symptoms – drug-induced hypersensitivity  syndrome",
abstract="Drug rash with eosinophilia and systemic symptoms (DRESS) – drug-induced hypersensitivity syndrome (DIHS) is one of the serious, potentially life-threatening reactions of hypersensitivity to drugs. The clinical symptoms occur after 3 to  8 weeks from beginning therapy with some drugs (carbamazepine, dapsone, salazosulfapyridine, phenobarbital, phenytoin, allopurinol, mexiletine, minocycline). The syndrome is characterized by fever of at least 38°C, dermatitis, internal organ involvement and usually prolonged course, lasting many months. DRESS/DIHS is identified seldom and probably a proportion of cases remain in the spectrum of misdiagnosed idiopathic skin disorders, including erythroderma. In 2006 diagnostic criteria were established: 1) maculopapular rash developing > 3 weeks after starting therapy with a limited number of drugs, 2) lymphadenopathy, 3) fever (> 38°C), 4) leukocytosis (> 10 × 109/l) – atypical lymphocytosis, eosinophilia, 5) hepatitis (ALT > 100 U/l), 6) HHV-6 reactivation. Diagnosis of typical syndrome is based on confirmation of all six criteria. Current data concerning aetiopathogenesis, clinical picture, diagnostics and treatment of DRESS/DIHS are presented. Key words: drug rash, hepatitis, HHV-6 reactivation.",
author="Lis-Święty, Anna
and Brzezińska-Wcisło, Ligia
and Bergler-Czop, Beata",
url="https://www.termedia.pl/Drug-rash-with-eosinophilia-and-systemic-symptoms-drug-induced-hypersensitivity-syndrome,7,15268,1,1.html"
}